CLINICAL TRIALS PROFILE FOR VOCLOSPORIN
✉ Email this page to a colleague
All Clinical Trials for voclosporin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00244842 ↗ | Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis | Completed | Aurinia Pharmaceuticals Inc. | Phase 3 | 2004-12-01 | The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo. |
| NCT00258713 ↗ | A 36-Week Extension to Protocol ISA04-03 | Completed | Aurinia Pharmaceuticals Inc. | Phase 3 | 2005-09-01 | The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis. |
| NCT00270634 ↗ | Study of ISA247 (Voclosporin) in De Novo Renal Transplantation | Completed | Aurinia Pharmaceuticals Inc. | Phase 2 | 2006-01-01 | This study will see if voclosporin is safe and effective in preventing kidney transplant rejection. |
| NCT00408187 ↗ | Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients | Completed | Aurinia Pharmaceuticals Inc. | Phase 3 | 2006-12-01 | The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis. |
| NCT01236287 ↗ | Special Access for the Use of Voclosporin for Kidney Transplantation | Available | Weill Medical College of Cornell University | 1969-12-31 | Voclosporin is an investigational medication previously studied to prevent acute rejection in patients who receive a kidney transplant. This study is a compassionate release program where subjects previously participating in the study entitled A Phase 2B, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 and Tacrolimus (Prograf®) in denovo Renal Transplant Patients (ISA05-01)" may be eligible to continue to receive voclosporin despite the Phase 2B study being terminated by the sponsor. Under the compassionate release program, subjects previously taking voclosporin may continue to receive the study medication until the drug is FDA-approved and commercially available in the United States. | |
| NCT01243983 ↗ | Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis | Completed | Lux Biosciences, Inc. | Phase 3 | 2011-02-01 | The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis). |
| NCT01586845 ↗ | Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation | Withdrawn | Aurinia Pharmaceuticals Inc. | Phase 3 | 2013-03-01 | The purpose of this study is to demonstrate the efficacy and safety of voclosporin administered orally twice daily for the prevention of acute allograft rejection in recipients of a kidney transplant. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for voclosporin
Condition Name
Clinical Trial Locations for voclosporin
Trials by Country
Clinical Trial Progress for voclosporin
Clinical Trial Phase
Clinical Trial Sponsors for voclosporin
Sponsor Name
